NASDAQ:KYTX Kyverna Therapeutics (KYTX) Stock Price, News & Analysis $3.44 -0.13 (-3.64%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.42 -0.02 (-0.58%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kyverna Therapeutics Stock (NASDAQ:KYTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kyverna Therapeutics alerts:Sign Up Key Stats Today's Range$3.40▼$3.5650-Day Range$2.27▼$4.3952-Week Range$1.78▼$8.78Volume109,586 shsAverage Volume353,753 shsMarket Capitalization$148.68 millionP/E RatioN/ADividend YieldN/APrice Target$15.60Consensus RatingBuy Company Overview Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California. Read More Kyverna Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreKYTX MarketRank™: Kyverna Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 426th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingKyverna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKyverna Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Kyverna Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($3.29) to ($3.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kyverna Therapeutics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kyverna Therapeutics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKyverna Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kyverna Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.50% of the float of Kyverna Therapeutics has been sold short.Short Interest Ratio / Days to CoverKyverna Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kyverna Therapeutics has recently decreased by 38.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKyverna Therapeutics does not currently pay a dividend.Dividend GrowthKyverna Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.50% of the float of Kyverna Therapeutics has been sold short.Short Interest Ratio / Days to CoverKyverna Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kyverna Therapeutics has recently decreased by 38.42%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.38 News SentimentKyverna Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Kyverna Therapeutics this week, compared to 7 articles on an average week.Search Interest5 people have searched for KYTX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Kyverna Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kyverna Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders22.00% of the stock of Kyverna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 18.08% of the stock of Kyverna Therapeutics is held by institutions.Read more about Kyverna Therapeutics' insider trading history. Receive KYTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KYTX Stock News HeadlinesKyverna Appoints New CFO to Guide Next Growth PhaseJuly 29, 2025 | msn.comKyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T FranchiseJuly 29, 2025 | prnewswire.comI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal just triggered a key alert in Tim Sykes’ system… and the setup looks strong. | Timothy Sykes (Ad)KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJuly 2, 2025 | globenewswire.comKyverna Therapeutics Names Marc Grasso Chief Financial OfficerJune 30, 2025 | marketwatch.comKyverna Therapeutics Announces Appointment of New Chief Financial OfficerJune 30, 2025 | finance.yahoo.com3 Promising Penny Stocks With Market Caps Over $100MJune 10, 2025 | finance.yahoo.comKyverna Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | prnewswire.comSee More Headlines KYTX Stock Analysis - Frequently Asked Questions How have KYTX shares performed this year? Kyverna Therapeutics' stock was trading at $3.74 at the start of the year. Since then, KYTX stock has decreased by 8.0% and is now trading at $3.44. How were Kyverna Therapeutics' earnings last quarter? Kyverna Therapeutics, Inc. (NASDAQ:KYTX) issued its quarterly earnings data on Tuesday, May, 13th. The company reported ($1.03) earnings per share for the quarter, topping analysts' consensus estimates of ($1.21) by $0.18. When did Kyverna Therapeutics IPO? Kyverna Therapeutics (KYTX) raised $319 million in an initial public offering (IPO) on Thursday, February 8th 2024. The company issued 14,500,000 shares at a price of $22.00 per share. Who are Kyverna Therapeutics' major shareholders? Kyverna Therapeutics' top institutional investors include Kera Capital Partners Inc. (0.98%), TD Asset Management Inc (0.58%), Y Intercept Hong Kong Ltd (0.10%) and Vanguard Personalized Indexing Management LLC (0.04%). View institutional ownership trends. How do I buy shares of Kyverna Therapeutics? Shares of KYTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kyverna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kyverna Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings5/13/2025Today8/03/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KYTX Previous SymbolNASDAQ:KYTX CIK1994702 Webkyvernatx.com Phone510-626-8331FaxN/AEmployees96Year FoundedN/APrice Target and Rating Average Price Target for Kyverna Therapeutics$15.60 High Price Target$24.00 Low Price Target$5.00 Potential Upside/Downside+353.5%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($3.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$127.48 million Net MarginsN/A Pretax MarginN/A Return on Equity-51.66% Return on Assets-45.92% Debt Debt-to-Equity RatioN/A Current Ratio7.44 Quick Ratio7.44 Sales & Book Value Annual Sales$7.03 million Price / Sales21.15 Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book0.56Miscellaneous Outstanding Shares43,220,000Free Float33,711,000Market Cap$148.68 million OptionableOptionable Beta3.04 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:KYTX) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.